Clinical trials: Tay-Sachs Disease Ganglioside
Gangliosidoses, GM1 Gangliosidosis
Registry Gangliosidoses
The clinical project "Eight At One Stroke: Attention Gangliosidoses" represents a clinical registry for recording the clinical manifestation and the disease progression of gangliosidoses.
- Conditions
- Gangliosidoses, GM1 Gangliosidosis, Morquio B Disease, Sialidosis
- Trial name
- NCT04624789
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- SphinCS Lyso Gemeinnutzige UG (Haftungsbeschrankt)
G(M2) Ganglioside, Tay-Sachs Disease Ganglioside
A Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis
Adult Tay-Sachs disease and Sandhoff diseases are caused by deficiency of an enzyme called β-hexosaminidase A, or Hex A in short.
- Conditions
- G(M2) Ganglioside, Tay-Sachs Disease Ganglioside, Sandhoff Disease Ganglioside
- Trial name
- NCT00679744
- Testing
- Pyrimethamine
- Where
- 3 sites in United States, Canada
- Sponsor
- Exsar Corporation
Multiple Myeloma
Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma
This study will test the ability of a specially designed monoclonal antibody to destroy multiple myeloma cells. This antibody is unique in its ability to promote the death of multiple myeloma cells by processes known as antibody…
- Trial name
- NCT00775502
- Testing
- BIW-8962
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Tay-Sachs Disease Ganglioside, Sandhoff Disease Ganglioside
Translational Potential of ex Vivo Gene Therapy in GM2 Gangliosidosis
The project aims to optimize and validate this new therapeutic strategy using cells from GM2 patients to evaluate the cross-correction of neurons in vitro by the culture medium of genetically modified myeloid cell lines.
- Trial name
- GM2-TGEX (NCT07445490)
- Testing
- blood sample
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Primary Stage II Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known whether vaccine therapy is more effective than observation alone for melanoma.
- Trial name
- NCT00005052
- Testing
- GM2-KLH vaccine, QS21, adjuvant therapy
- Where
- 80 sites in Australia, Belgium and 16 more
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Tay Sachs Disease, Sandhoff Disease
Gene Therapy for Tay-Sachs Disease
Hypothesis: To study the natural history of Tay-Sachs disease and evaluate therapeutic interventions. This study is intended to work in collaboration with NCT00668187 "A Natural History Study of Hexosaminidase Deficiency."…
- Conditions
- Tay Sachs Disease, Sandhoff Disease, Late Onset Tay Sachs Disease
- Trial name
- NCT01869270
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- University of Minnesota
Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma, Phase 2 Portion : Small Cell Lung Cancer(SCLC)
Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer
This Phase 1/2 study is designed to assess the following: safety and tolerability of BIW-8962, Dose Limiting Toxicities (DLTs), Maximum Tolerated Dose (MTD), Recommended Phase 2 Dose (RP2D) in Phase 1 in subjects with…
- Trial name
- NCT01898156
- Testing
- BIW-8962
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Kyowa Kirin Korea Co., Ltd.